Onconic Therapeutics KRX:476060KOSDAQ

온코닉테라퓨틱스 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days38
DART filings, 7 days0
Articles tracked40since Sep 11

In Q2 2026, Onconic Therapeutics reported operating profit of ₩2.8bn. Onconic Therapeutics (온코닉테라퓨틱스) appeared in 38 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 28 with 37 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside DongKookPharmaceutical, Daewoong Pharma and Celltrion.

Filing signals Profit +50% Screener

Onconic Therapeutics quarterly results separate, KRW

QuarterOperating profitNet income
Q2 2026₩2.8bn₩3.8bn
Q1 2026₩4.6bn₩6.4bn
Q4 2025 derived₩1.6bn₩4.7bn
Q3 2025₩8.3bn₩9.4bn
Q2 2025₩1.1bn−₩156m
Q1 2025₩1.6bn₩1.9bn
Q4 2024 derived₩1.4bn₩5.6bn
Q3 2024−₩2.4bn−₩2.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Onconic Therapeutics top stories 2 weeks, by number of outlets

  1. 1
    온코닉테라퓨틱스, 비만 신약 후보물질 공개…11월 美 학회서 발표
    10 outlets · 10 articlesFirst report Sep 28 08:57 아시아경제
  2. 2
    온코닉테라퓨틱스, 미국 비만학회서 차세대 신약 후보물질 최초 공개
    4 outlets · 4 articlesFirst report Sep 28 08:55 더페어뉴스
  3. 3
  4. 4
  5. 5
    온코닉테라퓨틱스, 글로벌 비만학회서 미공개 신약후보물질 첫 공개
    2 outlets · 2 articlesFirst report Sep 28 10:08 한국경제TV
  6. 6

Latest Onconic Therapeutics news Korean headlines